69 related articles for article (PubMed ID: 32565967)
1. The systematic identification of survival-related alternative splicing events and splicing factors in glioblastoma.
Peng T; Liu Z; Zhang Y; Liu X; Zhao L; Ma Y; Fan J; Song X; Wang L
Ann Hum Genet; 2024 Feb; ():. PubMed ID: 38369937
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Chemoresistance in Ovarian Cancer: Emerging Hallmarks, Signaling Mechanisms and Alternative Pathways.
Zaib S; Javed H; Rana N; Zaib Z; Iqbal S; Khan I
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38275065
[TBL] [Abstract][Full Text] [Related]
3. Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data.
Dellinger AE; Nixon AB; Pang H
Cancer Inform; 2014; 13(Suppl 4):1-9. PubMed ID: 25125969
[TBL] [Abstract][Full Text] [Related]
4. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
5. Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis.
Wang Q; Chang Z; Liu X; Wang Y; Feng C; Ping Y; Feng X
J Med Internet Res; 2024 Jan; 26():e48527. PubMed ID: 38252469
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns.
Mhatre A; Koroth J; Manjunath M; Kumar S S; Gawari R; Choudhary B
Front Genet; 2023; 14():1102114. PubMed ID: 37091785
[No Abstract] [Full Text] [Related]
8. Comprehensive characterization of the alternative splicing landscape in ovarian cancer reveals novel events associated with tumor-immune microenvironment.
Sun D; Zhao X; Yu Y; Li W; Gu P; Zhi Z; Xu D
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35137909
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
Sato M; Sato S; Shintani D; Hanaoka M; Ogasawara A; Miwa M; Yabuno A; Kurosaki A; Yoshida H; Fujiwara K; Hasegawa K
BMC Cancer; 2022 Jan; 22(1):59. PubMed ID: 35027024
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data.
Ye P; Yang Y; Zhang L; Zheng G
Front Oncol; 2021; 11():658262. PubMed ID: 34676158
[TBL] [Abstract][Full Text] [Related]
11. Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells.
Lee J; Chen R; Mohanakumar T; Bremner R; Mittal S; Fleming TP
Onco Targets Ther; 2021; 14():3813-3820. PubMed ID: 34188489
[TBL] [Abstract][Full Text] [Related]
12. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
Zhu J; Chen Z; Yong L
Gynecol Oncol; 2018 Feb; 148(2):368-374. PubMed ID: 29191436
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
14. Systematic Profiling of Alternative Splicing Events in Ovarian Cancer.
Liu J; Lv D; Wang X; Wang R; Li X
Front Oncol; 2021; 11():622805. PubMed ID: 33763357
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer.
Muñoz-Galván S; Carnero A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439181
[TBL] [Abstract][Full Text] [Related]
16. Chemoresistance-associated alternative splicing signatures in serous ovarian cancer.
Sun T; Yang Q
Oncol Lett; 2020 Jul; 20(1):420-430. PubMed ID: 32565967
[TBL] [Abstract][Full Text] [Related]
17. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
